The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial (HYVALUE)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Intervention Values Affirmation
Control Values Affirmation
Sponsored by

About this trial
This is an interventional health services research trial for Hypertension focused on measuring Hypertension, Medication Adherence, Values Affirmation, African Americans
Eligibility Criteria
Inclusion Criteria:
- Hypertension diagnosis: primary or secondary ICD-10 code diagnosis in last 24 mo
- SBP >140 mm Hg or DBP >90 mm Hg in last 12 months
- Currently taking antihypertensive medications
- Medications filled within health system's pharmacy
- White or African American, self-reported race
- Upcoming primary care visit
- Ability to read and write English
Exclusion Criteria:
- Pregnancy-related hypertension
- Dialysis-dependent end-stage renal disease
- Prisoners
- Unable to provide consent
Sites / Locations
- Denver Health and Hospital Authority
- Kaiser Permanente of Colorado
- Kaiser Permanente Mid Atlantic States
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Intervention Values Affirmation
Control Values Affirmation
Arm Description
The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
Outcomes
Primary Outcome Measures
Change in Antihypertensive Medication Adherence using Pharmacy Records
This antihypertensive medication adherence outcome will be a summary measure of adherence which assesses the proportion of days covered (PDC) over the period of observation for which a patient obtains antihypertensive medications. Adherence will be calculated for each antihypertensive drug in the regimen and combined across drugs into a summary measure of adherence for the entire drug regimen.
Change in Antihypertensive Medication Adherence using Self-Reported Adherence
This antihypertensive medication adherence outcome will be a summary measure of self-reported adherence using the validated Voils instrument, which has 3 questions that address adherence over the previous 7 days.
Change in Antihypertensive Medication Adherence using Pill Counts
This antihypertensive medication adherence outcome will be a summary outcome measure of adherence where if x is the number of pills in the bottle, y is the number of pills that would have been in the bottle had all pills been taken since the bottle was filled, and z is the number of pills that should have been taken since the last fill, and adherence is calculated as 1- [(x-y)/z].
Secondary Outcome Measures
Systolic Blood Pressure
Systolic blood pressure over time
Proportion of Time Blood Pressure is Under Control
Defined as the proportion of time over the 6-months of follow-up with a BP ≤ 140/90 mmHg.
Average Treatment Intensification
Calculated by subtracting the number of expected intensifications (number of visits after enrollment with a BP ≥140/90 mm Hg) from the number of observed intensifications (either an increase in dose or addition of a new medication class), and then dividing this difference by the number of office visits over the observation period.
Full Information
NCT ID
NCT03028597
First Posted
January 17, 2017
Last Updated
November 15, 2022
Sponsor
University of Colorado, Denver
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), University of Colorado, Boulder, Kaiser Permanente, Denver Health and Hospital Authority
1. Study Identification
Unique Protocol Identification Number
NCT03028597
Brief Title
The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial
Acronym
HYVALUE
Official Title
Using Values Affirmation to Reduce the Effects of Stereotype Threat on Hypertension Disparities: The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
January 2017 (Actual)
Primary Completion Date
May 2021 (Actual)
Study Completion Date
May 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
National Heart, Lung, and Blood Institute (NHLBI), University of Colorado, Boulder, Kaiser Permanente, Denver Health and Hospital Authority
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective of this study is to reduce the effects of stereotype threat on the adherence of African American patients with hypertension.
The specific aims of this study, which employs a values affirmation intervention, are to:
Compare the effects of the values-affirmation exercise to a control condition on antihypertensive medication adherence in African American patients with uncontrolled hypertension across three clinical settings,
Compare the effects of the values-affirmation exercise on antihypertensive medication adherence in African American patients and white patients with uncontrolled hypertension and similar socioeconomic characteristics, and
Evaluate the intervention for widespread dissemination using the RE-AIM (reach, effectiveness, adoption, implementation and maintenance) framework
Detailed Description
One in 3 US adults has hypertension and African Americans are disproportionately affected; almost 40% of non-Hispanic blacks have hypertension. Although the rates of uncontrolled hypertension have been decreasing in all groups, African Americans continue to have higher rates of uncontrolled hypertension compared to white Americans. The Institute of Medicine, World Health Organization and others have identified poor adherence to medications as the most significant, modifiable contributor to uncontrolled hypertension.
Stereotype threat may contribute to low adherence. Stereotype threat occurs when cues in the environment (such as visiting a doctor's office) trigger the threat of confirming, as self-characteristic, a negative stereotype about one's group. Although any individual may experience stereotype threat, African Americans are at greater risk due to widespread racism and past experiences of discrimination.
Values affirmation interventions reduce stereotype threat and decrease racial disparities in various outcomes. Values affirmation exercises typically ask participants to write a few sentences about their core values. By focusing on values that are important to them, values affirmation bolsters a person's self-concept by helping them view themselves as adequate, effective, and able to control important outcomes in spite of a possible threat.
Based on the evidence supporting the effectiveness of values affirmation in educational and other settings, the investigators hypothesize that values affirmation can similarly reduce racial disparities in medication adherence and subsequent health outcomes. By asking participating intervention patients to engage in a values affirmation exercise at an initial appointment with a primary care provider, the investigators hope to improve hypertensive medication adherence, systolic blood pressure, time under blood pressure control, and treatment intensification, and to reduce racial disparities in these outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Medication Adherence, Values Affirmation, African Americans
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
960 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention Values Affirmation
Arm Type
Experimental
Arm Description
The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
Arm Title
Control Values Affirmation
Arm Type
Active Comparator
Arm Description
The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
Intervention Type
Behavioral
Intervention Name(s)
Intervention Values Affirmation
Intervention Description
Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
Intervention Type
Behavioral
Intervention Name(s)
Control Values Affirmation
Intervention Description
Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
Primary Outcome Measure Information:
Title
Change in Antihypertensive Medication Adherence using Pharmacy Records
Description
This antihypertensive medication adherence outcome will be a summary measure of adherence which assesses the proportion of days covered (PDC) over the period of observation for which a patient obtains antihypertensive medications. Adherence will be calculated for each antihypertensive drug in the regimen and combined across drugs into a summary measure of adherence for the entire drug regimen.
Time Frame
Baseline, 3 and 6 months
Title
Change in Antihypertensive Medication Adherence using Self-Reported Adherence
Description
This antihypertensive medication adherence outcome will be a summary measure of self-reported adherence using the validated Voils instrument, which has 3 questions that address adherence over the previous 7 days.
Time Frame
Baseline, 3 and 6 months
Title
Change in Antihypertensive Medication Adherence using Pill Counts
Description
This antihypertensive medication adherence outcome will be a summary outcome measure of adherence where if x is the number of pills in the bottle, y is the number of pills that would have been in the bottle had all pills been taken since the bottle was filled, and z is the number of pills that should have been taken since the last fill, and adherence is calculated as 1- [(x-y)/z].
Time Frame
Baseline, 3 and 6 months
Secondary Outcome Measure Information:
Title
Systolic Blood Pressure
Description
Systolic blood pressure over time
Time Frame
Baseline, 3 and 6 months
Title
Proportion of Time Blood Pressure is Under Control
Description
Defined as the proportion of time over the 6-months of follow-up with a BP ≤ 140/90 mmHg.
Time Frame
6 months
Title
Average Treatment Intensification
Description
Calculated by subtracting the number of expected intensifications (number of visits after enrollment with a BP ≥140/90 mm Hg) from the number of observed intensifications (either an increase in dose or addition of a new medication class), and then dividing this difference by the number of office visits over the observation period.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Hypertension diagnosis: primary or secondary ICD-10 code diagnosis in last 24 mo
SBP >140 mm Hg or DBP >90 mm Hg in last 12 months
Currently taking antihypertensive medications
Medications filled within health system's pharmacy
White or African American, self-reported race
Upcoming primary care visit
Ability to read and write English
Exclusion Criteria:
Pregnancy-related hypertension
Dialysis-dependent end-stage renal disease
Prisoners
Unable to provide consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stacie L Daugherty, MD, MSPH
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
Denver Health and Hospital Authority
City
Denver
State/Province
Colorado
ZIP/Postal Code
80204
Country
United States
Facility Name
Kaiser Permanente of Colorado
City
Denver
State/Province
Colorado
ZIP/Postal Code
80205
Country
United States
Facility Name
Kaiser Permanente Mid Atlantic States
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20852
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
No plan to share IPD at this time.
Citations:
PubMed Identifier
35418247
Citation
Henderson KH, Helmkamp LJ, Steiner JF, Havranek EP, Vupputuri SX, Hanratty R, Blair IV, Maertens JA, Dickinson M, Daugherty SL. Relationship Between Social Vulnerability Indicators and Trial Participant Attrition: Findings From the HYVALUE Trial. Circ Cardiovasc Qual Outcomes. 2022 May;15(5):e007709. doi: 10.1161/CIRCOUTCOMES.120.007709. Epub 2022 Apr 14.
Results Reference
derived
PubMed Identifier
34913976
Citation
Daugherty SL, Helmkamp L, Vupputuri S, Hanratty R, Steiner JF, Blair IV, Dickinson LM, Maertens JA, Havranek EP. Effect of Values Affirmation on Reducing Racial Differences in Adherence to Hypertension Medication: The HYVALUE Randomized Clinical Trial. JAMA Netw Open. 2021 Dec 1;4(12):e2139533. doi: 10.1001/jamanetworkopen.2021.39533.
Results Reference
derived
PubMed Identifier
30907744
Citation
Daugherty SL, Vupputuri S, Hanratty R, Steiner JF, Maertens JA, Blair IV, Dickinson LM, Helmkamp L, Havranek EP. Using Values Affirmation to Reduce the Effects of Stereotype Threat on Hypertension Disparities: Protocol for the Multicenter Randomized Hypertension and Values (HYVALUE) Trial. JMIR Res Protoc. 2019 Mar 25;8(3):e12498. doi: 10.2196/12498.
Results Reference
derived
Learn more about this trial
The Multicenter Randomized HYpertension and VALUEs (HYVALUE) Trial
We'll reach out to this number within 24 hrs